Department of Nephrology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, Hubei, China.
Int Urol Nephrol. 2019 Dec;51(12):2227-2233. doi: 10.1007/s11255-019-02256-5. Epub 2019 Aug 28.
The prevalence of asymptomatic HUA is increasing year after year. HUA is a risk factor for the occurrence and development of renal diseases. However, the role of urate-lowering therapy in asymptomatic HUA complicated by renal damage is still controversial. In some experiments, the treatment of asymptomatic HUA complicated by renal damage may delay the progression of kidney damage. In addition, there is increasing evidence, suggesting that elevated serum uric acid is an independent risk factor for kidney disease. However, in other studies, uric acid-lowering therapy did not improve renal function, and uric acid levels could not be used as an independent predictor for CKD development. Further experimental studies are needed to determine the starting threshold and target value of asymptomatic HUA complicated by renal damage. At the same time, confirmation of the benefits of urate-lowering therapy for kidneys requires studies with larger samples and high-quality RCTs.
无症状高尿酸血症的患病率逐年增加。高尿酸血症是肾脏疾病发生和发展的危险因素。然而，降尿酸治疗在无症状高尿酸血症合并肾损害中的作用仍存在争议。在一些实验中，治疗无症状高尿酸血症合并肾损害可能会延缓肾损害的进展。此外，越来越多的证据表明，血清尿酸升高是肾脏疾病的独立危险因素。然而，在其他研究中，降尿酸治疗并未改善肾功能，尿酸水平不能作为 CKD 发展的独立预测因子。需要进一步的实验研究来确定无症状高尿酸血症合并肾损害的起始阈值和目标值。同时，降尿酸治疗对肾脏的益处需要更大样本量和高质量 RCT 研究的证实。
